Stockhub

Hansa Biopharma AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 03:5303:53, 16 August 2022 >Paris 1,189 bytes +1,189 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patie..."
Retrieved from "https://stockhub.co/research/Hansa_Biopharma_AB"